Cerevel (CERE) - מכפיל EV/EBITDA

Cerevel Therapeutics (CERE), developing with the support of AbbVie, is creating advanced therapies for Parkinson's disease and schizophrenia. The company leverages robotic laboratories and AI to design compounds targeting CNS pathologies. The price action on the GURU.Markets platform chart shows that the separate_ev_ebitda metric stands at . However, financial stability is constrained by high costs and the probability of regulatory drug rejections.
cerevel.com (CERE) - פילוחי מדדים ודוחות פיננסיים

Investors face a choice between the asset's current overvaluation and its growth potential amid high risks. This EV/EBITDA multiple compares total market capitalization plus debt against operating profit before taxes, allowing for an assessment of the business's real value. For Cerevel Therapeutics (CERE), this indicator is critical in the context of the acquisition by AbbVie and the success of emraclidine and tavapadone.